SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending as community members rally behind the stock, fueled by potential catalysts like a new CEO announcement and optimism around future interest rate cuts. The stock's recent surge has sparked discussions of a potential short squeeze and gamma squeeze, with retail investors expressing strong bullish sentiment. A well-known celebrity recently announced their support of $OPEN adding fuel to the fire.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to a land sale agreement potentially boosting its NAV, attracting attention for its small float and potential for a significant upward move. Community discussions highlight the possibility of a short squeeze, comparing it to other recent low float runners. The stock's low float and increasing volume are key talking points.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the community anticipates upcoming earnings, speculating on profitability and potential impacts from new ventures like trading cards and the collectibles market. Some traders are weighing the possibility of a Roaring Kitty return, while others debate the stock's long-term prospects and the potential for market manipulation. There's also discussion of a possible Lego partnership and its impact on revenue.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is trending amid speculation of a potential acquisition following leadership changes, with Nestle being a frequently mentioned suitor. Community discussions focus on the possibility of a merger or strategic partnership to bolster the company's finances and pipeline. The stock's high short interest and low float are also fueling hopes for a potential short squeeze.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending amid discussions about its AI capabilities and potential, with community members debating whether the market is properly valuing its AI narrative. Some are pointing to significant buybacks and undervaluing while others are cautious, citing volatility and the company's AI transition. Overall, conversation is centered on Baidu's potential for growth in the AI sector.

Forward Industries, Inc. engages in the provision of integrated design, development, and manufacturing solutions for top tier medical and technology customers worldwide. It operates through the following segments: OEM Distribution, Retail Distribution, and Design. The OEM Distribution segment sources and distributes carrying cases and other accessories for medical monitoring and diagnostic kits and a variety of other portable electronic and non-electronic devices. The Retail Distribution segment sells smart-enabled furniture and a variety of other products through agreements with various retailers, both in stores and through online retailer websites. The Design segment provides hardware and software product design and engineering services. The company was founded in 1961 and is headquartered in Hauppauge, NY.

Forward Industries, Inc.

Forward Industries ($FORD) is trending due to a significant after-hours surge, driven by speculative momentum and social media buzz, despite no clear news catalyst. The community is actively discussing whether this surge is sustainable, with some mistaking it for Ford Motor Company ($F), while others point to its low float and potential for a short squeeze. Overall, Forward Industries is attracting attention as a low-float stock with potential for volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is trending amid discussions about its connections to political figures, the launch of a Trump-backed stablecoin, and general market volatility. The community is expressing concerns about potential financial risks and ethical considerations, with some questioning the company's fundamentals. Commentary ranges from political accusations to speculation about the stock's future performance.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is trending due to anticipation surrounding its upcoming earnings announcement, which will be unusually presented from the floor of the NYSE, fueling speculation of major news. The community is actively discussing potential partnerships, buyouts, and a positive forward outlook. Investors are also eyeing the company's strong revenue growth and AI capabilities within the burgeoning space economy.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending following the launch of its new AI model, Qwen-3-Max, and reports of a new AI chip, fueling optimism about the company's AI capabilities and cloud growth potential. Community discussions revolve around price targets, potential for a short squeeze, and comparisons to other tech giants like Nvidia. Broader market context includes renewed investor confidence in Chinese tech stocks and speculation about future growth in the AI sector.

Brewski

BREWSKI.X is trending as the community discusses potential whale activity and its potential as the "next runner." Amidst this, some users are also pointing to concerns of a potential rug pull due to the homepage being taken down. The token is also being associated with a patriotic, "America is back" narrative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus Pharmaceuticals, representing an 8.5% downside from the last close.The research firm maintained a 'Neutral' rating on the stock.Last week, Supernus said it would acquire Sage for $8.5 per share in cash, plus a contingent value right (CVR) worth up to $3.5, based on commercial milestones for Zurzuvae, an FDA-approved treatment for postpartum depression co-developed with Biogen.&nbsp;The total transaction value of up to $12 per share reflects a 79% premium to Sage’s last closing price before the announcement.The deal, expected to close in the third quarter of 2025, is intended to expand Supernus’ neuropsychiatry portfolio and&nbsp;could reduce annual costs by up to&nbsp;$200 million.The company also guaranteed a cash payout at closing, excluding value from the CVR, which remains contingent on future sales performance.&nbsp;Several other firms adjusted their price targets in response to the Supernus deal: Piper Sandler lowered its target to $8.50 from $9,&nbsp;while Truist raised its target to $9 from $8&nbsp;and Canaccord increased its target to $8.50 from $8, each maintaining a ‘Hold’ or ‘Neutral’ rating.&nbsp;BofA removed its rating altogether, stating that Sage shares are no longer trading on fundamentals following the acquisition announcement.H.C. Wainwright noted the $22.4 million breakup fee may not be large enough to prevent a competing offer, particularly from Biogen, which already co-commercializes Zurzuvae with Sage in the U.S.In January, Sage Therapeutics’ board&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-gains-onfda-nod-for-leqembi-dosing/chblEfgRYE">unanimously rejected</a> Biogen's unsolicited offer to acquire all outstanding shares for $7.22 per share.&nbsp;The company said the offer “significantly undervalued” Sage and was not in the best interest of shareholders.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Shares of Sage Therapeutics closed up 1.9% at $9.3 on Friday. The stock has risen 60.9% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Equity

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening">acquire</a> Sage Therapeutics, Inc. (SAGE) for up to $795 million. SAGE stock traded 34% higher on Monday morning following the announcement.Under the terms of the deal, Supernus intends to acquire Sage for a total consideration of $12 per share in cash, including $8.50 per share payable at closing and a contingent value right (CVR) worth up to $3.50 per share in cash. The CVR is payable upon achieving certain net sales and commercial milestones, the companies said.The total consideration represents a premium of about 79% from SAGE’s closing price of $6.7 on Friday.The transaction is expected to close in the third quarter of 2025 and strengthen Supernus’ neuropsychiatry portfolio with the addition of Zurzuvae, the only oral medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with postpartum depression.Zurzuvae was co-developed by Sage and Biogen, Inc. (BIIB). Through a collaboration agreement with Biogen, Supernus will report collaboration revenue that is 50% of the total net revenue Biogen records for Zurzuvae in the U.S.In 2024 alone, Sage recorded a collaboration revenue of $36.1 million from net sales of Zurzuvae.Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, Onapgo, and Gocovri.The acquisition is also expected to be significantly accretive in 2026, with cost synergies of up to $200 million on an annual basis, the companies said.On Stocktwits, retail sentiment around SUPN jumped from ‘neutral’ to ‘bullish territory over the past 24 hours, while chatter increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_18_03_AM_png_8f57b78080.webp" alt="Screenshot 2025-06-16 at 10.18.03 AM.png" width="625" height="68"><figcaption>SUPN's Sentiment Meter and Message Volume as of 10:15 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around SAGE increased from ‘neutral’ to ‘extremely bullish’ territory while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_24_57_AM_png_4d871e71b4.webp" alt="Screenshot 2025-06-16 at 10.24.57 AM.png" width="628" height="67"><figcaption>SAGE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>This year, <a href="https://stocktwits.com/symbol/SAGE">SAGE stock</a> has risen 56% while <a href="https://stocktwits.com/symbol/SUPN">SUPN stock</a> fell about 10%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-organization-enters-telecom-market-touts-us-made-phone/chlntPmRRR8">Trump Organization Enters Telecom Market, Touts US-Made Phone Amid President’s Push To Reshore Smartphone Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Sage Therapeutics, Inc. (NASDAQ: SAGE), today announced that it will host a live webcast on Tuesday, February 11, 2025 at 4:30 p.m. ET to review fourth quarter and full year 2024 financial results...

Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered fallout from a rejected acquisition proposal.Sage Therapeutics announced its board had unanimously rejected Biogen's unsolicited Jan. 10&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sage-stock-soars-on-biogen-bid/chGN0nXRNV">offer</a> to acquire all outstanding Sage shares for $7.22 per share.&nbsp;The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.Sage's board also revealed plans to explore strategic alternatives, cautioning that a transaction is not guaranteed.&nbsp;Meanwhile, Sage reaffirmed its commitment to establishing Zurzuvae as the standard treatment for postpartum depression.&nbsp;Biogen, which co-markets Zurzuvae, had argued that full ownership would aid its rollout but expressed little interest in Sage's broader pipeline when it placed its bid.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BIIB_sentiment_and_message_volume_Jan_27_d1b89b799f.png" alt="BIIB sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>BIIB sentiment and message volume Jan 27 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Following the rejection, retail sentiment for Biogen turned 'bearish' on Stocktwits, with increased message volume reflecting investor concerns about the deal's implications.<stembedurl>https://stocktwits.com/Gito/message/601644664</stembedurl><stembedurl>https://stocktwits.com/Scanners_Free/message/601610361</stembedurl>However, Biogen received a significant boost as the FDA on Sunday approved a supplemental biologics license application for Leqembi, developed in collaboration with Eisai Co. Ltd.&nbsp;The new label allows for once-every-four-weeks intravenous maintenance dosing following an 18-month initiation phase of biweekly treatments.Leqembi, used to treat early-stage Alzheimer's disease, addresses patients with mild cognitive impairment or mild dementia.&nbsp;The updated dosing regimen is expected to improve patient compliance while enhancing convenience.However, Biogen's challenges remain stark; the stock has lost nearly 40% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogens Unsolicited Acquisition Proposal

Sage Therapeutics, Inc. (Nasdaq: SAGE) (Sage or the Company), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board intends...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.83	--	--	N/A
Q2 '25	-$0.94	-$0.79	16.12%	BEAT
Q1 '25	-$0.99	-$1.01	-1.53%	MISSED
Q4 '24	-$1.48	-$1.56	-5.17%	MISSED
Q3 '24	-$1.54	-$1.53	0.80%	BEAT

SAGE
Sage Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest SAGE News

SAGE Sage Therapeutics Inc